GlassScriptPhysician profile
Cecilia E Avila
NPI 1730424284
$5,198.16
in general payments reported to CMS, 2019-2025
30 companies · $65.37 in 2025
The $65.37 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,458 · 2022: $1,286 · 2023: $1,093 · 2024: $1,296 · 2025: $65.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.63 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.96 | 2021-2025 | |
| Novo Nordisk INC | $782.80 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $641.16 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $523.26 | 2021-2024 | Prolia, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.70 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $269.26 | 2021-2023 | |
| Glaxosmithkline, LLC. | $220.35 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $206.28 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $169.02 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $90.73 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $90.72 | 2023-2024 | Voquezna |
| Pfizer INC. | $85.08 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $85.00 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Ardelyx, INC. | $84.78 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $79.72 | 2022-2023 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $77.04 | 2024-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $76.94 | 2022-2024 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $73.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $70.77 | 2022-2023 | |
| Phadia US INC. | $43.61 | 2023-2024 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $41.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.54 | 2022 | |
| Genentech USA, INC. | $37.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.61 | 2023 | Livalo, Seglentis |
| Travere Therapeutics, INC. | $20.18 | 2023 | |
| Intuity Medical INC | $16.41 | 2022 | |
| Seqirus USA INC | $14.97 | 2022 | |
| Hologic Sales and Service, LLC | $14.82 | 2024 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.